Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -72,522 | -31,508 | -71,898 | -47,509 | -24,749 |
| Depreciation Amortization | 17 | 8 | N/A | N/A | N/A |
| Accounts receivable | 303 | 119 | -355 | -655 | -436 |
| Other Working Capital | 23,513 | 12,679 | -7,470 | -3,487 | -7,600 |
| Other Operating Activity | -596 | -437 | -1,450 | -541 | -376 |
| Operating Cash Flow | $-49,285 | $-19,139 | $-81,173 | $-52,192 | $-33,161 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -48,157 | -55,893 | -160,472 | -152,383 | -156,390 |
| PPE Investments | -59 | -59 | N/A | N/A | N/A |
| Investing Cash Flow | $-48,216 | $-55,952 | $-160,472 | $-152,383 | $-156,390 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 116,262 | 149 | 203,184 | 203,174 | 202,990 |
| Other Financing Activity | -209 | 116,056 | 64 | 0 | 0 |
| Financing Cash Flow | $116,053 | $116,205 | $203,248 | $203,174 | $202,990 |
| Beginning Cash Position | 49,304 | 49,304 | 87,701 | 87,701 | 87,701 |
| End Cash Position | 67,856 | 90,418 | 49,304 | 86,300 | 101,140 |
| Net Cash Flow | $18,552 | $41,114 | $-38,397 | $-1,401 | $13,439 |
| Free Cash Flow | |||||
| Operating Cash Flow | -49,285 | -19,139 | -81,173 | -52,192 | -33,161 |
| Capital Expenditure | -59 | -59 | N/A | N/A | N/A |
| Free Cash Flow | -49,344 | -19,198 | -81,173 | -52,192 | -33,161 |